Press Releases AXIM Biotechnologies, Inc.

Equities

AXIM

US05463V1008

Market Closed - OTC Markets Other stock markets 15:45:02 2024-07-01 EDT			5-day change	1st Jan Change
0.0148 ^USD	+49.49%		+102.74%	-22.11%

05-20	AXIM Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-16	AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024	03-27	AQ
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation	02-20	AQ
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production	12-20	AQ
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease	23-09-12	BU
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test	23-08-01	BU
AXIM Biotechnologies - Optometric Management, Perform a Pre-Fit Ocular Surface Evaluation	23-07-26	AQ
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide	23-07-12	AQ
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch	23-05-24	AQ
AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit	23-05-23	AQ
AXIM BIOTECHNOLOGIES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-04-17	AQ
AXIM® Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays	23-04-11	AQ
AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing	23-03-14	AQ
AXIM BIOTECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	23-01-27	AQ
AXIM Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance	23-01-17	AQ
AXIM Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call	23-01-12	AQ
AXIM® Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call	23-01-11	PR
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent	22-12-13	GL
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent	22-12-13	AQ
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions	22-12-06	GL
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions	22-12-06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AXIM Biotechnologies, Inc.

Equities

AXIM

US05463V1008

Press Releases

Filters